Understanding how LINE1 retrotransposons affect immune responses in acute myeloid leukemia
Dissecting the functional role of LINE1 retrotransposon-mediated interferon signaling in myeloid leukemia
This study is looking at how certain genetic elements called LINE1 might help the immune system fight against acute myeloid leukemia (AML), a type of blood cancer, and it hopes to find new ways to boost the body's defenses against this disease.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10890151 on NIH RePORTER |
What this research studies
This research investigates the role of LINE1 retrotransposons in acute myeloid leukemia (AML), a serious blood cancer. The study aims to understand how these genetic elements influence immune signaling pathways, particularly the type I interferon response, which may affect the growth and survival of leukemia cells. By using advanced techniques like CRISPR, researchers will explore how reactivating LINE1 can trigger immune responses that could potentially halt leukemia progression. This could lead to new therapeutic strategies that enhance the body's ability to fight AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with acute myeloid leukemia.
Not a fit: Patients with other types of leukemia or those who are younger than 21 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that improve outcomes for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results in targeting retrotransposons and immune pathways in various cancers, suggesting that this approach may be effective in AML as well.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Lee, Michael — Ut Southwestern Medical Center
- Study coordinator: Lee, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.